Cargando…

The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer

SIMPLE SUMMARY: The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system. We hypothesized that immunofunctional phenotyping that represent the malfunction of the CIC is clinically relevant in breast cancer (BC) utilizing total of 2979...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, Takashi, Torigoe, Toshihiko, Yan, Li, Huang, Jing Li, Yamashita, Hiroko, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795596/
https://www.ncbi.nlm.nih.gov/pubmed/33396390
http://dx.doi.org/10.3390/cancers13010110
_version_ 1783634482363891712
author Takeshita, Takashi
Torigoe, Toshihiko
Yan, Li
Huang, Jing Li
Yamashita, Hiroko
Takabe, Kazuaki
author_facet Takeshita, Takashi
Torigoe, Toshihiko
Yan, Li
Huang, Jing Li
Yamashita, Hiroko
Takabe, Kazuaki
author_sort Takeshita, Takashi
collection PubMed
description SIMPLE SUMMARY: The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system. We hypothesized that immunofunctional phenotyping that represent the malfunction of the CIC is clinically relevant in breast cancer (BC) utilizing total of 2979 BC cases; 1075 from TCGA cohort, 1904 from METABRIC cohort were analyzed. The immunofunctional phenotype was classified as follows: hot T-cell infiltrated, high immune cytolytic activity (CYT), cold T-cell infiltrated, high frequency of CD8+ T cells and low CYT, and non-inflamed, low frequency of CD8+ T cells and low CYT. We demonstrated that immunofunctional phenotyping not only indicated the degree of anti-cancer immune dysfunction, but also served as a prognostic biomarker and HTI was inversely related to estrogen response. ABSTRACT: The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system. We hypothesized that immunofunctional phenotyping that represent the malfunction of the CIC is clinically relevant in breast cancer (BC). Total of 2979 BC cases; 1075 from TCGA cohort, 1904 from METABRIC cohort were analyzed. The immunofunctional phenotype was classified as follows: hot T-cell infiltrated (HTI), high immune cytolytic activity (CYT), Cold T-cell infiltrated (CTI), high frequency of CD8+ T cells and low CYT, and non-inflamed, low frequency of CD8+ T cells and low CYT. The analysis of tumor immune microenvironment in the immunofunctional phenotype revealed that not only immunostimulatory factors, but also immunosuppressive factors were significantly elevated and immunosuppressive cells were significantly decreased in HTI. Patients in HTI were significantly associated with better survival in whole cohort and patients in CTI were significantly associated with worse survival in triple negative. Furthers, HTI was inversely related to estrogen responsive signaling. We demonstrated that immunofunctional phenotype not only indicated the degree of anti-cancer immune dysfunction, but also served as a prognostic biomarker and HTI was inversely related to estrogen response.
format Online
Article
Text
id pubmed-7795596
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77955962021-01-10 The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer Takeshita, Takashi Torigoe, Toshihiko Yan, Li Huang, Jing Li Yamashita, Hiroko Takabe, Kazuaki Cancers (Basel) Article SIMPLE SUMMARY: The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system. We hypothesized that immunofunctional phenotyping that represent the malfunction of the CIC is clinically relevant in breast cancer (BC) utilizing total of 2979 BC cases; 1075 from TCGA cohort, 1904 from METABRIC cohort were analyzed. The immunofunctional phenotype was classified as follows: hot T-cell infiltrated, high immune cytolytic activity (CYT), cold T-cell infiltrated, high frequency of CD8+ T cells and low CYT, and non-inflamed, low frequency of CD8+ T cells and low CYT. We demonstrated that immunofunctional phenotyping not only indicated the degree of anti-cancer immune dysfunction, but also served as a prognostic biomarker and HTI was inversely related to estrogen response. ABSTRACT: The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system. We hypothesized that immunofunctional phenotyping that represent the malfunction of the CIC is clinically relevant in breast cancer (BC). Total of 2979 BC cases; 1075 from TCGA cohort, 1904 from METABRIC cohort were analyzed. The immunofunctional phenotype was classified as follows: hot T-cell infiltrated (HTI), high immune cytolytic activity (CYT), Cold T-cell infiltrated (CTI), high frequency of CD8+ T cells and low CYT, and non-inflamed, low frequency of CD8+ T cells and low CYT. The analysis of tumor immune microenvironment in the immunofunctional phenotype revealed that not only immunostimulatory factors, but also immunosuppressive factors were significantly elevated and immunosuppressive cells were significantly decreased in HTI. Patients in HTI were significantly associated with better survival in whole cohort and patients in CTI were significantly associated with worse survival in triple negative. Furthers, HTI was inversely related to estrogen responsive signaling. We demonstrated that immunofunctional phenotype not only indicated the degree of anti-cancer immune dysfunction, but also served as a prognostic biomarker and HTI was inversely related to estrogen response. MDPI 2020-12-31 /pmc/articles/PMC7795596/ /pubmed/33396390 http://dx.doi.org/10.3390/cancers13010110 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Takeshita, Takashi
Torigoe, Toshihiko
Yan, Li
Huang, Jing Li
Yamashita, Hiroko
Takabe, Kazuaki
The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
title The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
title_full The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
title_fullStr The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
title_full_unstemmed The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
title_short The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer
title_sort impact of immunofunctional phenotyping on the malfunction of the cancer immunity cycle in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795596/
https://www.ncbi.nlm.nih.gov/pubmed/33396390
http://dx.doi.org/10.3390/cancers13010110
work_keys_str_mv AT takeshitatakashi theimpactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT torigoetoshihiko theimpactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT yanli theimpactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT huangjingli theimpactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT yamashitahiroko theimpactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT takabekazuaki theimpactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT takeshitatakashi impactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT torigoetoshihiko impactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT yanli impactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT huangjingli impactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT yamashitahiroko impactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer
AT takabekazuaki impactofimmunofunctionalphenotypingonthemalfunctionofthecancerimmunitycycleinbreastcancer